How much does a box of Imfinzi cost in 2025

Durvalumab enhances the anti-tumor immune response by blocking the interaction between tumor cells and the immune system. It is mainly used to treat various malignant tumors such as non-small cell lung cancer, small cell lung cancer, and biliary tract cancer. It needs to be used in medical institutions through intravenous infusion.

How much does a box of imfinzi cost in 2025

The price of imfinzi in 2025 may be affected by multiple factors. The following information is for reference only. The actual price is subject to the official release of that year.

Launching and price status

The specification of the generic drug durvalumab is 500mg/10ml, and the price of the Abraxis BioScience version in the United States is about US$664 per box. Imrvalumab was launched in China in 2019 and is not yet covered by medical insurance. Patients need to purchase it at their own expense.

Factors affecting price fluctuations

The launch of biosimilars may drive down the price of original drugs. Fluctuations in raw material production costs, cold chain transportation costs and exchange rate changes will all affect terminal pricing. The approaching end of the patent protection period may prompt companies to adjust their price strategies in advance, so the above prices are for reference only.

Patients need to purchase durvalumab through domestic hospital pharmacies or formal online drug purchase channels. Durvalumab should be stored in an environment of 2-8°C away from light.

Potential side effects of durvalumab

Immunotherapy may cause unique reactions, and patients should promptly identify and deal with side effects to treatment.

Immune-related pneumonia

The incidence rate is about 5%, which is characterized by persistent dry cough, shortness of breath or fever. Mild symptoms require suspension of medication and oral prednisone as directed by the doctor; severe symptoms require hospitalization for intravenous hormone therapy. It is recommended to conduct a baseline pulmonary function test before treatment and review chest CT every 6 weeks after treatment.

Skin toxic reactions

35% of patients will experience rash or itching, mostly on the trunk and limbs. For mild rash, 0.1% mometasone furoate cream can be applied topically, twice a day. When blisters or ulcers occur, oral antihistamines must be combined, and immunotherapy should be suspended until symptoms subside. Avoid using alkaline shower gel on a daily basis and wear pure cotton clothing.

Abnormal thyroid function

20% of patients will develop hyperthyroidism or hypothyroidism, manifesting as palpitations, sudden weight changes, or fatigue. TSH and FT4 indicators need to be tested every month. Patients with hyperthyroidism can take β-blockers to relieve symptoms, while patients with hypothyroidism need to supplement levothyroxine (25-50 μg/day). After symptoms stabilize, it is still recommended to review thyroid function every 3 months.

Precautions for durvalumab

In special circumstances, the treatment plan needs to be adjusted. The following content is for patient reference. Please consult your doctor for guidance.

Risks of allogeneic hematopoietic stem cell transplantation

Patients who have received hematopoietic stem cell transplantation may develop graft-versus-host disease (GVHD), manifested as skin erythema, diarrhea, or abnormal liver function. Blood images need to be closely monitored during treatment, and immunotherapy drugs should be stopped immediately if suspected symptoms occur. The use of durvalumab should be administered at least 6 months after transplantation, and the risks should be assessed by a hematologist.

Risk of infection

Immunotherapy may increase the probability of bacterial or fungal infection, especially lung infection. Patients need to use prophylactic antibiotics under the guidance of a doctor. If you develop fever or cough up purulent sputum, you should seek emergency medical attention.

Daily care requires keeping the living environment ventilated, eating mainly cooked food, and eating fruits after peeling them. Record body temperature and bowel movements during treatment. If diarrhea or vomiting lasts for more than 3 days, please contact the attending doctor.